Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 90 results for adalimumab

  1. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

    NICE guideline
    Published
    3 May 2019
    View recommendations

    Sections for NG130

  2. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    26 August 2015
    View recommendations

    Sections for TA352

  3. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  4. Bimekizumab for treating active psoriatic arthritis (TA916)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA916

  5. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA456

  6. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    6 August 2013
    View quality statements

    Sections for QS40

  7. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA905

  8. What are the benefits, risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with placebo for induction of remission for people with subacute ulcerative colitis that is refractory to systemic corticosteroids?

    risks and cost effectiveness of methotrexate, ciclosporin, tacrolimus, adalimumab and infliximab compared with each other and with...

    Research recommendation
    Published
    25 October 2019

  9. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued [GID-TAG400]

    Technology appraisal guidance
    Discontinued

  10. Management of inflammatory arthritis

    targets. Many of the most commonly prescribed biological DMARDs, such as adalimumab and etanercept, belong to a class of medicines...

  11. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  12. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  13. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    N/A Source guidance details Comes from guidance Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children

    Research recommendation
    Published
    15 October 2018

  14. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    of value. Source guidance details Comes from guidance Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and

    Research recommendation
    Published
    15 March 2016

  15. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA350